THERAPY DOSSIER · th-aef2d041fba5

SC-51089 (selective EP1 receptor antagonist)

Drug · SC-51089 is a selective prostaglandin EP1 receptor antagonist (research tool); no confident ChEMBL name match returned

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: SC-51089 is a selective prostaglandin EP1 receptor antagonist (research tool); no confident ChEMBL name match returned
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25426930 ↗2014No effect reported

Role of the prostaglandin E2 EP1 receptor in traumatic brain injury.

MouseTBIControlled cortical impactC57BL/6 wild-type and EP1 receptor knockoutMalen = 6 to 9 per group for lesion and oedema; 6 to 8 and 6 to 7 p…Subcutaneous100 micrograms/kg (a lower dose of 20 micrograms/kg was ini…First injection immediately after controlled cortical impact, second at 24 hour…

Model: Controlled cortical impact traumatic brain injury

Neither post-treatment with SC-51089 nor genetic deletion of the EP1 receptor significantly altered cortical lesion volume, hippocampal swelling or neurological deficit scores at 24 and 48 hours, and injury-induced Iba1 and GFAP increases were unaffected.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.

Loading the evidence…